权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Understanding the AGL metastasis suppressor for therapeutic gain

了解 AGL 转移抑制因子的治疗效果

基本信息

批准号：
9223676
负责人：
DAN THEODORESCU
金额：
$ 43.54万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-12-01 至 2018-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9223676
关键词：
American Autophagocytosis Biological Assay Biological Markers Bladder Bladder Neoplasm Bladder Urothelium CD44 gene Cancer Biology Cancer Death Rates Cells Cessation of life Clinical Clinical Trials Data Death Rate Dependence Development Diagnosis Disease Enzymes Exhibits Federal Government Foundations Future Gene Components Gene Targeting Genes Genomics Glucose Glycogen Glycolysis Goals Growth Guanosine Triphosphate Phosphohydrolases HMMR gene Human Hyaluronic Acid In Vitro Individual Knockout Mice Knowledge Lead Libraries Link Location Malignant Neoplasms Malignant neoplasm of urinary bladder Medicare Membrane Metabolic Modeling Molecular Target Mus Neoplasm Metastasis Pathway interactions Patients Pharmacology Phenotype Predictive Value Primary Neoplasm Production RNA Interference Receptor Inhibition Recurrence Resources Role SLC2A1 gene Signal Transduction Source Testing Therapeutic Translating Tumor Cell Line Tumor Suppressor Genes Urothelium Visceral Work Xenograft procedure biomarker panel biomarker-driven cancer cell cancer recurrence cancer type carcinogenesis cell growth chemical carcinogenesis cost expectation experimental study extracellular glucosidase glycogenolysis high risk in vivo inhibitor/antagonist innovation killings neoplastic cell new therapeutic target novel novel therapeutics outcome forecast pre-clinical prognostic assays prognostic value public health relevance receptor research clinical testing small hairpin RNA therapeutic development therapeutic target tumor tumor growth tumor initiation tumor metabolism tumor progression tumorigenesis whole genome

项目摘要

DESCRIPTION (provided by applicant): Bladder cancer kills 15,000 annually and because of few therapeutic advances there is a need for innovation. This project has discovered suppressors of bladder tumor growth and metastasis and shown that low expression of AGL, an enzyme involved in glycogenolysis, and RhoGDI2, an inhibitor of multiple GTPases, is associated with cancer recurrence and death. The Goal of this continuation project is to understand how reduced AGL levels result in aggressive bladder cancer and to translate this knowledge into novel therapies. We found bladder cancer cells with low AGL express elevated levels of Hyaluronic Acid (HA) synthase 2 (HAS2), and its extracellular product HA, and have activated RhoC and Rac1, known drivers of tumor progression. We demonstrated RhoC/Rac1 activity is suppressed by RhoGDI2, linking the actions of the two metastasis suppressors. Cells with low AGL also exhibit increased glycolysis, glucose import and autophagy. When either glucose import or autophagy are blocked, low AGL tumor cells show greater reduction of in vitro growth than cells with higher AGL levels, exposing a vulnerability of these aggressive cells. These data support an innovative Hypothesis: Tumor cells with low AGL generate growth and metastatic signals via production of HA, activation of its receptors CD44 and RHAMM, and downstream effectors such as RhoC and Rac1. For these signals to be actualized, sufficient energy needs to be provided via enhanced glucose import and autophagy. Three Specific Aims will test this hypothesis. 1) Evaluate impact of HA signaling on aggressiveness of bladder cancers with low AGL. We will determine if HA drives tumor progression via its receptors CD44 and RHAMM and effectors RhoC and Rac1 that are inhibited by RhoGDI2. Experiments will use RNAi and receptor inhibition in human xenografts. 2) Determine role of the AGL signaling network in bladder cancer development and progression. We will evaluate the independent predictive value of tumor suppressor genes and components of the AGL signaling network in a large panel of annotated human tumors, to define a predictive multigene biomarker signature and possible new therapeutic targets. We will use full and conditional (bladder urothelium) AGL knockout mice in a chemical carcinogenesis model that generates spontaneous visceral metastases to test whether lack of AGL makes urothelium more susceptible to carcinogenesis and resulting tumors more aggressive. 3) Target molecular vulnerabilities of bladder cancers with low AGL expression. Here we test whether blocking glucose import and/or autophagy reduces in vivo bladder tumor growth. We will use shRNA and pharmacologic agents already in preclinical/clinical testing. We will screen shRNA libraries to metabolic and autophagy genes in cells with low AGL to discover novel genes essential to the aggressive tumor phenotype, with the expectation that some of these will become therapeutic targets. We will evaluate combined inhibition of HA signaling and energy production pathways with the expectation this will have synergistic detrimental effects on tumor progression. Impact: This project will lay the foundation for future biomarker-driven personalized clinical trials that target critical vulnerabilities in bldder cancer while informing us on how AGL executes its unanticipated role in cancer.